A Biotech Slump Is Emptying Labs and Threatening Research on New Drugs
Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 US workers who lost their jobs this
2023-11-23 02:47
Broadcom Secures $28.4 Billion Debt Financing for VMware Buy
Broadcom Inc. has secured up to $28.4 billion in new debt commitments to fund its purchase of VMware
2023-08-18 04:23
Sage Tumbles as Depression Pill Approval Omits Major Disorder
Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum
2023-08-07 20:15
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal
Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion, including debt, to expand its rare disease
2023-07-28 22:57
Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
2023-07-11 11:20
Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy
Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from US regulators, a move that will help widen insurance
2023-07-07 08:48
How a Japanese Drugmaker Clinched Win Over Alzheimer’s
(This story was originally published Sept. 29. On Thursday, the US Food and Drug Administration granted full approval
2023-07-07 08:46